Suppr超能文献

[接受左甲状腺素钠治疗的甲状腺癌患者的骨组织矿物质密度]

[Bone tissue mineral density in patients with thyroid gland cancer on levothyroxine natrium therapy].

作者信息

Khmara I M, Tolkachev Iu V

出版信息

Klin Med (Mosk). 2005;83(10):61-5.

Abstract

The subjects of the study were 319 patients (55 men and 264 women) aged 17 to 55 (mean age 40.8 +/- 1.9 years), who had been on suppressive therapy with levothyroxine natrium in a dose of 100 to 300 mkg/day, or 247 +/- 0.32 mkg/kg/day, for 4.9 0.3 years following special treatment of diferentiated thyroid gland cancer (TGC). The control group included 55 subjects (11 men and 44 women) aged 18 to 55 (mean age 38.9 +/- 1.4 years) without thyroid gland dysfunction. In the patients of the main group bone mineral density (BMD) was determined by means of dual-energy x-ray absorptiometry using Sophos L-XRA device (France). Serum levels of free fractions of thyroid hormones and thyrotropin were measured by radioimmunoassay (RIA) using Medipan diagnostic (Germany) and Immunotech (Czechia) kits. Blood levels of testosterone, estradiol, lutropin, and follicle-stimulating hormone were determined by RIA using IOPIBOKH (Belarus) kit in order to exclude the role of sex hormone deficit in BMD disorder. Peripheral blood level of parathormone was determined by RIA using CIS Biointernational (France). General calcium levels were determined by arsenazo III method, inorganic phosphorus level--by kinetic phosphomolybdic method using Technicon RA-XT analyzer (USA), ionized calcium serum level--by ionoselective method using OP-270 analyzer (Radelkis, Hungary) and DiaSys kits (Russia). The study revealed no increase of osteoporosis frequency in patients under 55 years old on suppressive therapy with levothyroxine natrium following a surgery for differentiated TGC. The study found a significant increase in frequency of lumbar osteopenia (22.9% vs. 9.1% in the control group, chi squared = 3.9, p = 0.049) due to decrease of skeleton mineralization in women (21.96% vs. 681% in the control group, chi squared = 4.02, p = 0.045), which was associated with peripheral blood level of triiodothyronine (T3) free fraction (r = -0.45, p = 0.03.) Subjects with a level of T3 free fraction higher than 5.8 mmol/l displayed a significant increase of calcium excretion: 4.6 +/- 0.2 mmol/day vs. 3.7 +/- 0.2 mmol/day in the control group, T = 3.06, p = 0.049); a weak correlation between T3 free fraction level higher than 5.8 mmol/l and calcium excretion (r = 0.28, p = 0.002) was found The study revealed age peaks of osteopenia in the women of the main group--25 years old and older than 40. The results show that postoperative parathyroid insufficiency does not lead to decrease of skeleton mineralization.

摘要

该研究的对象为319例患者(55名男性和264名女性),年龄在17至55岁之间(平均年龄40.8±1.9岁),这些患者在分化型甲状腺癌(TGC)经过特殊治疗后,接受左甲状腺素钠抑制治疗,剂量为100至300微克/天,即247±0.32微克/千克/天,持续4.9±0.3年。对照组包括55名受试者(11名男性和44名女性),年龄在18至55岁之间(平均年龄38.9±1.4岁),无甲状腺功能障碍。在主要组的患者中,使用法国的索福斯L-XRA设备通过双能X线吸收法测定骨矿物质密度(BMD)。使用德国的Medipan诊断试剂盒和捷克的Immunotech试剂盒通过放射免疫分析(RIA)测量甲状腺激素游离部分和促甲状腺激素的血清水平。为了排除性激素缺乏在骨密度紊乱中的作用,使用白俄罗斯的IOPIBOKH试剂盒通过RIA测定睾酮、雌二醇、促黄体生成素和促卵泡激素的血液水平。使用法国的CIS Biointernational试剂盒通过RIA测定外周血甲状旁腺激素水平。总钙水平通过偶氮胂III法测定,无机磷水平通过使用美国Technicon RA-XT分析仪的动力学磷钼酸法测定,离子钙血清水平通过使用匈牙利Radelkis的OP-270分析仪和俄罗斯DiaSys试剂盒的离子选择性方法测定。该研究表明,分化型TGC手术后接受左甲状腺素钠抑制治疗的55岁以下患者骨质疏松症发生率没有增加。该研究发现,由于女性骨骼矿化减少,腰椎骨质减少的发生率显著增加(22.9%对对照组的9.1%,卡方=3.9,p=0.049),这与游离三碘甲状腺原氨酸(T3)的外周血水平相关(r=-0.45,p=0.03)。游离T3水平高于5.8毫摩尔/升的受试者钙排泄显著增加:4.6±0.2毫摩尔/天对对照组的3.7±0.2毫摩尔/天,T=3.06,p=0.049);发现游离T3水平高于5.8毫摩尔/升与钙排泄之间存在弱相关性(r=0.28,p=0.002)。该研究揭示了主要组女性骨质减少的年龄高峰——25岁及40岁以上。结果表明,术后甲状旁腺功能减退不会导致骨骼矿化减少。

相似文献

2
Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
J Bone Miner Res. 1997 Jan;12(1):72-7. doi: 10.1359/jbmr.1997.12.1.72.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验